ACCESS Newswire
09 Jun 2021, 18:35 GMT+10
SAN MATEO, CA / ACCESSWIRE / June 9, 2021 / iTolerance, Inc. ('iTolerance' or the 'Company'), a biotechnology company focused on the development of innovative regenerative medicines, today announced the formation of its Executive Leadership Team with the hiring of Anthony Japour, M.D. as Chief Executive Officer and Camillo Ricordi, M.D. as Chief Scientist.
Cameron Gray, Ph.D., J.D., founder and chairman of iTolerance, stated, 'We are extremely excited to launch iTolerance with the initial appointments to our executive team of Drs. Japour and Ricordi. iTolerance has a unique opportunity to develop a potential cure for Type 1 Diabetes and other regenerative medicine products that eliminate the need for chronic immunosuppression of patients. I believe that with Anthony and Camillo at the helm, iTolerance is well-positioned to develop and bring to market potentially curative treatments for diseases such as diabetes where there remains tremendous unmet medical need.'
'I am very pleased to join iTolerance and to lead this exciting new company that has a potential breakthrough technology to make a real difference in the lives of patients with Type 1 Diabetes and potentially other rare diseases. The scientific founders and advisors of iTolerance have worked tirelessly over many years pioneering regenerative cell therapy without immunosuppression as a platform technology. This platform technology fuels a robust pipeline in many high-value indications and importantly, areas of significant unmet medical need,' commented Dr. Japour. 'I look forward to working with Dr. Ricordi along with the rest of our team, scientific founders and advisors to advance the iTolerance pipeline forward.'
'Type 1 Diabetes, even with the currently available treatments, remains an area of significant unmet need. iTolerance has developed, what I believe to be a compelling potential cure for Type 1 Diabetes without immunosuppression, and I am excited to join iTolerance and aid in advancing this important program towards an IND and first-in-man study. With the addition of the regenerative cell therapy platform technology, I believe iTolerance could become a leader in the regenerative medicine space,' added Dr. Ricordi.
Anthony Japour, M.D.
Dr. Japour has over 30 years of experience as a physician and as a biotechnology and pharmaceutical executive. He began his career as an MD, trained at Harvard Medical School with subspecialty training in Infectious Diseases where he became an Assistant Professor of Medicine, and was awarded the prestigious American Foundation for AIDS Scholar award, followed by research grants from the Pediatric AIDS Foundation, a NIH-NIAID K-11 Physician Scientist Award and NIH RO1. Dr. Japour, holds a B.S from the University of Michigan, Ann Arbor and an M.D. from Northwestern University Medical School.
Additional career highlights include:
Camillo Ricordi, M.D.
The Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida
Acknowledged by his peers as one of the world's leading scientists in diabetes cure-focused research, cell transplantation and regenerative medicine, Dr. Ricordi is well-known for inventing the machine that made it possible to isolate large numbers of islet cells (insulin-producing cells) from the human pancreas and for performing the first series of successful clinical islet allotransplants that reversed diabetes after implantation of donor purified islets into the liver of recipients with diabetes. The procedure is now used by laboratories performing clinical islet transplants worldwide and in 2017 the first NIH funded, FDA Phase 3 multicenter trial was successfully completed by the NIH Clinical Islet Transplantation Consortium, chaired by Dr. Ricordi. He has also developed highly innovative strategies to transplant cells and organs without the continuous requirement for anti-rejection drugs and to reverse autoimmune disease conditions. He is currently ranked among the top ten world experts in transplantation of insulin producing cells for the treatment of diabetes and was appointed to the Supreme Council of Health (Consiglio Superiore di Sanita) by the Ministry of Health of Italy.
Additional career highlights include:
About ITOL-101
ITOL-101 is an innovative therapy initially being developed for the treatment of and potentially as a cure for Type 1 Diabetes. As an adjunct therapy with pancreatic islet cells, ITOL-101 creates a durable, localized immune tolerance that has the potential to protect implanted islet cells from rejection by the body's own immune system. This localized immune acceptance potentially eliminates the need for sustained immunosuppressants and allows for localized remodeling and functional engraftment.
About iTolerance, Inc.
iTolerance isa privately held biotechnology company focused on the development of innovative regenerative medicines. The Company's lead program, ITOL-101, is an adjunct therapy with pancreatic islet cell implant currently in development for the treatment of or as a potential breakthrough cure for Type 1 Diabetes. ITOL-101 has demonstrated compelling efficacy in non-human primate studies. The Company plans to advance ITOL-101 towards an IND and first-in-man study. Additionally, the Company is advancing its regenerative cell therapy platform to fuel a robust pipeline addressing high-value indications. For more information, please visit itolerance.com.
Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
[email protected]
SOURCE: iTolerance, Inc.
Get a daily dose of Chicago Chronicle news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Chicago Chronicle.
More InformationFRANKLIN, Tennessee: Hundreds of thousands of Nissan and Infiniti vehicles are being recalled across the United States due to a potential...
REDMOND, Washington: Microsoft is the latest tech giant to announce significant job cuts, as the financial strain of building next-generation...
LONDON UK - U.S. stock markets were closed on Friday for Independence Day. Global Forex Markets Wrap Up Friday with Greeback Comeback...
SANTA CLARA, California: Nvidia came within a whisker of making financial history on July 3, briefly surpassing Apple's all-time market...
SACRAMENTO, California: California's multibillion-dollar farms are facing a growing crisis—not from drought or pests, but from a sudden...
WASHINGTON, D.C.: President Donald Trump says the United States could soon reach a trade deal with India. He believes this deal would...
(Photo credit: Troy Taormina-Imagn Images) Bobby Jenks, a member of the 2005 Chicago White Sox World Series championship team, died...
(Photo credit: Patrick Gorski-Imagn Images) Yohel Pozo hit a pinch three-run homer to lift the visiting St. Louis Cardinals past...
(Photo credit: Brad Mills-Imagn Images) The Colorado Rockies have yet to win a home series this season, but they still have a chance...
(Photo credit: Peter Aiken-Imagn Images) Shohei Ohtani's ramp up toward becoming a full-fledged starting pitcher will continue Saturday...
(Photo credit: Joe Camporeale-Imagn Images) The Kansas City Royals have an opportunity to earn their first series win in Phoenix...
These July 4 protests stood in stark contrast to Trump's America 250 initiative, launched on Memorial Day in May to count down to the...